2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Hemorrhage
13
Neoplasms
7
Leiomyoma
7
Breast Neoplasms
6
Postoperative Hemorrhage
4
Hematologic Neoplasms
4
Thrombocytopenia
3
Myofibroma
3
Meningioma
3
Blood Loss, Surgical
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Seroma
2
Seizures
2
Prostatic Neoplasms
2
Postoperative Complications
2
Ovarian Neoplasms
2
Menorrhagia
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Bone Neoplasms
2
Wrist Fractures
1
Urologic Diseases
1
Urinary Tract Infections
1
Urinary Retention
1
Thromboembolism
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Interventions
Cyclophosphamide
87
fludarabine phosphate
86
Peripheral Blood Stem Cell Transplantation
71
Mycophenolic Acid
58
Tacrolimus
57
Busulfan
57
Whole-Body Irradiation
55
Antilymphocyte Serum
47
Cyclosporine
46
fludarabine
39
Methotrexate
38
Filgrastim
38
Melphalan
32
ruxolitinib
30
Cytarabine
30
Radiotherapy
27
Azacitidine
23
Etoposide
21
Methylprednisolone
20
Cord Blood Stem Cell Transplantation
18
Specimen Handling
15
Sirolimus
15
Granulocyte Colony-Stimulating Factor
15
Decitabine
15
Biopsy
15
Flow Cytometry
14
Cyclosporins
14
Alemtuzumab
14
thymoglobulin
13
venetoclax
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tranexamic Acid
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled